Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer Beats Street 2Q Forecasts Despite Big Drop in Profit

By AP | August 2, 2016

NEW YORK (AP) — Higher expenses offset a big jump in sales from an acquisition, as Pfizer Inc.’s second-quarter profit plunged 23 percent. The biggest U.S. drugmaker still beat Wall Street’s expectations.

Pfizer on Tuesday reported net income of $2.02 billion, or 33 cents per share, down from $2.63 billion, or 42 cents per share, in 2015’s second quarter.

The New York-based company said earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 64 cents per share. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 62 cents per share.

The maker of Viagra and the Prevnar 13 vaccine against pneumonia and other infections posted revenue of $13.15 billion in the period, up 11 percent from a year earlier. Three analysts surveyed by Zacks expected $13 billion.

Sales were boosted by last year’s acquisition of sterile injectable drugmaker Hospira, as well as rising sales in emerging markets such as China and India.

Pfizer’s innovative health business, which sells its drugs protected by patents, saw sales climb 7 percent, to $7.11 billion. Sales were led by fibromyalgia and pain treatment Lyrica, up 15 percent to $1.05 billion; new breast cancer drug Ibrance, which more than tripled to $514 million, and rheumatoid arthritis drug Zeljanz, up 70 percent to $217 million. Sales of older medicines, most of which have expired patents but still sell well in other countries, jumped 16 percent to $6.04 billion.

Pfizer affirmed its prior financial forecasts for 1016. It expects full-year earnings in the range of $2.38 to $2.48 per share, with revenue in the range of $51 billion to $53 billion.

Its shares fell 59 cents, or 1.6 percent, to $36.72 in premarket trading Tuesday.

Pfizer shares have risen 16 percent since the beginning of the year, while the Standard & Poor’s 500 index has risen 6 percent. The stock has increased slightly more than 4 percent in the last 12 months.

This story was generated by Automated Insights using data from Zacks Investment Research. Access a Zacks stock report on PFE at https://www.zacks.com/ap/PFE.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50